About OcellO
OcellO is a company based in Leiden (Netherlands) founded in 2011 was acquired by Crown Bioscience in May 2021. OcellO offers products and services including PDX Models, Genomics Services, Proteomics Services, CRISPR/Cas9 Services, and Bioanalytical Services. OcellO operates in a competitive market with competitors including Reaction Biology, ImmunoSCAPE, PhenoVista, Discovery Biomed and BCI Pharma, among others.
- Headquarter Leiden, Netherlands
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$325.75 K (USD), Grant
Jan 01, 2021
-
Investors
Crown Bioscience
& 1 more
-
Employee Count
Not available
-
Acquired by
Crown Bioscience
(May 05, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of OcellO
OcellO offers a comprehensive portfolio of products and services, including PDX Models, Genomics Services, Proteomics Services, CRISPR/Cas9 Services, and Bioanalytical Services.
Preclinical models for tumor drug testing and research
DNA sequencing and analysis for biomarker discovery
Mass spectrometry-based analysis for protein studies
Gene editing tools for cell line development
Testing for biomarkers and drug responses
Funding Insights of OcellO
Investors in OcellO
OcellO has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Crown Bioscience and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked | |
|
Cancer and CVMD drugs are developed using PDX models.
|
Locked | Locked | Locked |
Investor details for OcellO
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by OcellO
Investment portfolio details for OcellO
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - OcellO
Detailed financials for OcellO
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ocello Comparisons
Peer comparison for OcellO
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of OcellO
OcellO operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Reaction Biology, ImmunoSCAPE, PhenoVista, Discovery Biomed and BCI Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
In vitro enzyme activity assays, secializing in kinase & epigenetic HTS and profiling
|
|
| Locked | Locked | Locked |
High-dimensional immune profiling services are delivered via proprietary platform.
|
|
| Locked | Locked | Locked |
A CRO that provides phenotypic assay development and screening services.
|
|
| Locked | Locked | Locked |
Custom human cell engineering and drug discovery services are provided.
|
|
| Locked | Locked | Locked |
Contract research services in cancer and neuroinflammation are offered.
|
|
| Locked | Locked | Locked |
Specialised CRO offering a range of screening platforms for cardiac safety testing, ion channel profiling and in vitro HTS screening
|
Detailed competitors of OcellO
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ocello
Complete news archive for OcellO
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OcellO
OcellO was founded in 2011 and raised its 1st funding round 6 years after it was founded.
OcellO is headquartered in Leiden, Netherlands. It is registered at Leiden, South Holland, Netherlands.
OcellO is a CRO that provides 3D screening services for drug discovery. It has a proprietary high throughput system for 3D imaging and phenotypic profiling that enables better quantification of complex biological phenomena combined with clinically relevant endpoints. Based on this platform, the company offers several drug screening and discovery services, including development of target-specific and immuno-oncology assays for screening drugs, phenotypic screening in disease models of interest and compound profiling, as well as a specialized drug candidate testing platform for polycystic kidney disease. In addition, OcellO offers in vitro 3D cell culture assays of patient-derived xenograft (PDX) mouse models for lead optimization, in partnership with Charles River Laboratories.
OcellO's top competitors include ImmunoSCAPE, Quantumcyte and Reaction Biology.
OcellO offers PDX Models, Genomics Services, Proteomics Services, CRISPR/Cas9 Services, and Bioanalytical Services.
OcellO has 2 investors. Key investors include Crown Bioscience, and European Union.